Fluticasone furoate, umeclidinium and vilanterol dry powder triple therapy inhaler

Description

In this Product Explainer, Respiratory Physician Dr Kwok Yan explains the role of fluticasone furoate, umeclidinium and vilanterol dry powder triple therapy inhaler for the maintenance treatment of asthma in adult patients who are not adequately controlled with an ICS+LABA (7 mins).

This educational activity was developed by Healthed at the request of and with funding from GSK.

PM-AU-FVU-OGM-220003 approved June 2022

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Expert panel – Dr Georgia Rigas & A/Prof Samantha Hocking, facilitated by Dr Angela Kwong

Expert panel – Dr Georgia Rigas & A/Prof Samantha Hocking, facilitated by Dr Angela Kwong

Weight Management in Women of Reproductive Age

Jarrod Warner & Irene Schneider

Jarrod Warner & Irene Schneider

New Spirometry Standards: Key Changes for Clinical Practice

A/Prof Alberto Pinzon Charry

A/Prof Alberto Pinzon Charry

Food Allergy Prevention

A/Prof Daryl Cheng

A/Prof Daryl Cheng

Protecting Young Lungs – Paediatric Insights into RSV

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Dr Kwok Yan

expert

Dr Kwok Yan

Respiratory Physician

Date published: 14 June 2022